Publications
Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to treat AML
Novel CD33/CLL-1-directed dual CAR-T cells mediate potent antigen-specific cytolytic activity in mouse models of Acute Myeloid Leukemia (AML)
Analyzing Guide RNA (gRNA) Impurity Discovery & Quantification
Purification of CAR+ T Cells Reveals Impact of Untransduced Cells in CAR-T Drug Product
ADCs targeting CD45, a transmembrane receptor found on hematopoietic stem and progenitor cells (HSPCs) and mature leukocytes, have been developed and evaluated for allogeneic HCT in mice. In mouse models, CD45-ADCs show efficacy in depletion of HSPCs, successful donor engraftment across MHC barriers, and a favourable toxicity profile.
Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML
Uncovering Molecular and Functional Dynamics of Human Hematopoietic Stem Cells during In Vitro Culture for Cell Therapy Manufacturing